Insider Trading March 26, 2026

Verisign Executive Vice President Sells $124,500 in Stock as Company Posts Mixed Q4 Results

Thomas C. Indelicarto disposes of 498 shares; Verisign reports revenue beat but EPS misses expectations for Q4 2025

By Maya Rios VRSN
Verisign Executive Vice President Sells $124,500 in Stock as Company Posts Mixed Q4 Results
VRSN

Verisign (NASDAQ:VRSN) Executive Vice President, General Counsel, and Secretary Thomas C. Indelicarto sold 498 shares on March 25, 2026 for $124,500, according to a Form 4 filing. The transaction comes as the company reported mixed fourth-quarter 2025 results - a revenue beat alongside an EPS shortfall - and while the stock has risen modestly over the past week.

Key Points

  • Thomas C. Indelicarto sold 498 shares on March 25, 2026 for $250.0 per share, totaling $124,500, and now holds 39,198.258 shares directly.
  • VeriSign Inc.'s fourth-quarter 2025 results showed an EPS of $2.23 versus an expected $2.35 (a 5.11% negative surprise), while revenue came in at $425.3 million, beating expectations.
  • Market indicators cited include a share price of $250.81 (up about 5% over the past week), a market capitalization of $22.96 billion, gross profit margins of 88%, and a P/E ratio of 28.4; InvestingPro classifies the stock as slightly overvalued.

Insider transaction details

According to a Form 4 filing with the Securities and Exchange Commission, Thomas C. Indelicarto, who serves as Executive Vice President, General Counsel, and Secretary at Verisign (NASDAQ:VRSN), sold 498 shares of the company's common stock on March 25, 2026. The shares changed hands at $250.0 per share, producing a total transaction value of $124,500.

Following this disposition, Indelicarto's direct ownership in Verisign stands at 39,198.258 shares.


Market context and company metrics

At the time of reporting, Verisign's shares were trading at $250.81, reflecting a roughly 5% gain over the past week. InvestingPro analysis included with the filing indicates the company appears slightly overvalued. Verisign is reported to have a market capitalization of $22.96 billion, a gross profit margin of 88%, and a price-to-earnings ratio of 28.4.

For investors seeking more detailed valuation metrics, the company’s Pro Research Report on InvestingPro is cited as a source of additional analysis.


Recent financial results

VeriSign Inc. released its fourth-quarter 2025 earnings, delivering a mixed financial performance. The company reported earnings per share (EPS) of $2.23, which fell short of the $2.35 consensus expectation - a negative surprise of 5.11%.

At the same time, VeriSign reported revenue of $425.3 million, which exceeded expectations and represented a top-line beat. Market response to the quarterly release included an uptick in the company’s stock during the aftermarket trading session, suggesting investor optimism despite the EPS miss. Commentators in the filing noted that the aftermarket rise may reflect other favorable elements of the earnings report.

Analysts and market participants are expected to continue monitoring VeriSign’s forthcoming quarters for further signs of earnings momentum and valuation alignment.


Summary and implications

The reported insider sale by a senior executive coincides with a quarter in which Verisign posted stronger-than-expected revenue but missed on EPS. Company-level financial metrics remain notable - high gross margins and a mid-range P/E - while short-term stock movement has been positive. Investors and observers will likely weigh the combination of the insider transaction, valuation commentary from InvestingPro, and the mixed earnings print as they assess Verisign’s near-term outlook.

Risks

  • Earnings risk - VeriSign’s EPS for Q4 2025 missed consensus estimates by 5.11%, indicating potential volatility in reported profitability that could affect investor confidence.
  • Valuation risk - InvestingPro analysis suggests the company is slightly overvalued, which could expose the stock to downward pressure if growth expectations are not met.
  • Market reaction uncertainty - While aftermarket trading showed a rise in the stock following the earnings release, such sentiment can change quickly as analysts and investors digest subsequent data and guidance.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026